期刊文献+

8-epi-Liphagal的合成研究 被引量:1

Studies on the Total Synthesis of 8-epi-Liphagal
原文传递
导出
摘要 四环杂萜类天然产物Liphagal含有新奇的[6-7-5-6]四环骨架,是磷酸肌醇3-激酶(PI3K)的有效抑制剂之一,可以选择性抑制细胞增殖和促进细胞死亡,在治疗炎症、免疫紊乱、癌症以及心血管疾病中有潜在的医用价值.从廉价的2,4,5-三甲氧基苯甲醛出发,通过Wittig反应、Cu催化的环化反应、选择性氢化、分子内Friedel-Crafts反应,以直线步骤最长7步,8.72%的总收率实现了8-epi-Liphagal高级中间体10的合成. The tetracyclic meroterpenoid natural product(+)-liphagal is one of a number of natural inhibitors of phosphatidylinositol 3-kinase(PI3K),which plays a central role in regulation of cell proliferation,cell survival,adhesion,membrane trafficking,glucose transport and neurite growth.Liphagal also shows inhibitory activity against PI3Kα with an IC50of 100 nmol L-1 making it as an agent for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases.From a structural point of view,liphagal has an unprecedented [6-7-5-6] tetracyclic skeleton,and has attracted significant attention from the synthetic chemists.Starting from cheap and commercially available 2,4,5-trimethoxylbenzaldehyde and α-ionone,an advanced intermediate 10 for the synthesis of 8-epi-liphagal was achieved in the longest linear 7 steps and 8.72% yield.The key reactions include: Wittig reaction,Cu-catalyzed cyclization,chemoselective hydrogenation and Friedel-Crafts reaction.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2012年第21期2232-2235,共4页 Acta Chimica Sinica
基金 国家自然科学基金(Nos.21072085 20921120404 21102061 20972059 21290180) 教育部"111"计划和科技部"973"(No.2010CB833203) 卫生部重大科技专项(No.2012ZX09201101-003)资助~~
关键词 8-epi-Liphagal 天然产物 合成 FRIEDEL-CRAFTS反应 高级中间体 liphagal natural product synthesis Friedel-Crafts reaction advanced intermediates
  • 相关文献

参考文献14

  • 1Marion, F.; Williams, D. E.; Patrick, B. O.; Hollander, I.; Mallon, R.; Kim, S. C.; Roll, D. M.; Feldberg, L.; van Soest, R.; Andersen, R. J. Org. Lett. 2006, 8, 321.
  • 2Sundstrom, T. J.; Anderson, A. C.; Wright, D. L. Org. Biomol. Chem. 2009, 7, 840.
  • 3For recent reviews on the therapeutic potential of phosphoinosi- tide-3-kinase inhibitors, see: (a) Ward, S. G.; Sotsios, Y.; Dowden, J.; Bruce, I.; Finan, P. Chem. Biol. 2003, 10, 207; (b) Ward, S. G.; Finan, P. Curr. Opin. Pharmacol. 2003, 3, 426.
  • 4Andersen, R.; Hollander, I.; Roll, D. M.; Kim, S. C.; Mallon, R. G.; Williams, D. E.; Marion, F. W02006081659, 2006 [Chem. Abstr. 2006, 145, 230773].
  • 5Pereira, A. R.; Strangman, W. K.; Marion, F.; Feldberg, L.; Roll, D.; Mallon, R.; Hollander, I.; Ander- sen, R. J. d. Med. Chem. 2010, 53, 8523.
  • 6George, J. H.; Baldwin, J. E.; Adlington, R. M. Org. Lett. 2010 12, 2394.
  • 7Alvarez-Manzaneda, E.; Chahboun, R.; Alvarez, E. Cano, M. J.; Haidour, A.; Alvarez-Manzaneda, R. Org. Lett. 2010 12, 4450.
  • 8Day, J. J.; McFadden, R. M.; Virgil, S. C.; Kolding H.; Alleva, I. L.; Stoltz, B. M. Angew. Chem., Int. Ed. 2011, 50 6814.
  • 9For a recent synthetic study of 5-epi-liphagal, see: Zhang, J.; Li, L.; Wang, Y.; Wang, W.; Xue, J.; Li, Y. Org. Lett. 2012, 14, 4528.
  • 10Newman, S. G.; Aureggi, V.; Bryan, C. S.; Lautens, M. Chem. Commun. 2009, 5236.

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部